期刊
CURRENT CANCER DRUG TARGETS
卷 8, 期 8, 页码 733-740出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156800908786733504
关键词
PIK3CA; mutation; oncogene; PI3 kinase; AKT; mTOR
类别
资金
- The Flight Attendant's Medical Research Institute (FAMRI)
- NIH/NCI [CA109274]
- Summer Running Fund
- Cure Foundation
- Mary Kay Ash Charitable Foundation
- Avon Foundation
- Department of Defense Breast Cancer Research Program Predoctoral Fellowship Award [W81XWH-06-1-0325]
- NIH Institutional Training [T32 CA09071]
- ASCO Cancer Foundation Young Investigator Award
The development of targeted therapies with true specificity for cancer relies upon exploiting differences between cancerous and normal cells. Genetic and genomic alterations including somatic mutations, translocations, and amplifications have served as recent examples of how such differences can be exploited as effective drug targets. Small molecule inhibitors and monoclonal antibodies directed against the protein products of these genetic anomalies have led to cancer therapies with high specificity and relatively low toxicity. Recently, our group and others have demonstrated that somatic mutations in the PIK3CA gene occur at high frequency in breast and other cancers. Moreover, the majority of mutations occur at three hotspots, making these ideal targets for therapeutic development. Here we review the literature on PIK3CA mutations in cancer, as well as existing data on PIK3CA inhibitors and inhibitors of downstream effectors for potential use as targeted cancer therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据